Advertisement
Advertisement

RARE

RARE logo

Ultragenyx Pharmaceutical Inc.

24.81
USD
Sponsored
+0.29
+1.18%
Apr 17, 16:00 UTC -4
Closed
exchange

After-Market

24.90

+0.09
+0.36%

Ultragenyx Pharmaceutical Inc. Profile

About

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

Info & Links

CEO

Emil D. Kakkis

Headquarters

60 Leveroni Court
Novato, CA 94949, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.ultragenyx.com

Auditor

Ernst & Young LLP

Share holders

8

Employees

1,371

Ultragenyx Pharmaceutical Inc. Statistics

Valuation Measures

Market Capitalization2

2.45B

Enterprise Value

2.03B

Enterprise Value/EBITDA(ttm)

-4.02

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

3.49

Price to Book(mrq)

--

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

83.49%

Operating Margin(ttm)

-85.54%

Profit Margin(ttm)

-88.08%

Return on Equity(ttm)

-1024.42%

Return on Invested Capital(ttm)

-1989.81%

Return on Assets(ttm)

-43.10%

Income Statement

Revenue(ttm)

673.00M

Revenue Per Share(ttm)

6.96

Gross Profit(ttm)

564.00M

EBITDA(ttm)3

-504.00M

Net Income Available to Common(ttm)

-575.00M

Diluted EPS(ttm)

-5.84

Share Statistics

Beta (5Y Monthly)

0.25

52-Week Change

-30.48%

S&P 500 52-Week Change

38.15%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

96.63M

Dividend Yield

0.00%

Float4

93.19M

% Held by Insiders

5.20%

% Held by Institutions

97.67%

Balance Sheet

Total Cash(mrq)

680.00M

Total Cash Per Share(mrq)

7.04

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

2.48%

Quick Ratio(mrq)

2.34%

Book Value Per Share(mrq)

-0.83

Cash Flow

Operating Cash Flow Per Share(ytd)

-4.73

Free Cash Flow(ytd)

-472.00M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement